DE69433713D1 - Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen - Google Patents
Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungenInfo
- Publication number
- DE69433713D1 DE69433713D1 DE69433713T DE69433713T DE69433713D1 DE 69433713 D1 DE69433713 D1 DE 69433713D1 DE 69433713 T DE69433713 T DE 69433713T DE 69433713 T DE69433713 T DE 69433713T DE 69433713 D1 DE69433713 D1 DE 69433713D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- methods
- pharmaceutical compositions
- compositions useful
- neurological diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 8
- 229940114079 arachidonic acid Drugs 0.000 abstract 4
- 235000021342 arachidonic acid Nutrition 0.000 abstract 4
- 239000003921 oil Substances 0.000 abstract 3
- 230000000813 microbial effect Effects 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7350593A | 1993-06-09 | 1993-06-09 | |
US73505 | 1993-06-09 | ||
PCT/US1994/006317 WO1994028913A1 (en) | 1993-06-09 | 1994-06-02 | Methods and pharmaceutical compositions useful for treating neurological disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69433713D1 true DE69433713D1 (de) | 2004-05-19 |
DE69433713T2 DE69433713T2 (de) | 2005-04-07 |
Family
ID=22114083
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69435246T Expired - Lifetime DE69435246D1 (de) | 1993-06-09 | 1994-06-02 | Verwendung von Docosahexaensäure zur Herstellung eines Arzneimittels zur Behandlung der senilen Demenz und Alzheimer-Erkrankung |
DE69433713T Expired - Lifetime DE69433713T2 (de) | 1993-06-09 | 1994-06-02 | Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69435246T Expired - Lifetime DE69435246D1 (de) | 1993-06-09 | 1994-06-02 | Verwendung von Docosahexaensäure zur Herstellung eines Arzneimittels zur Behandlung der senilen Demenz und Alzheimer-Erkrankung |
Country Status (11)
Country | Link |
---|---|
EP (3) | EP1419780B1 (de) |
JP (3) | JPH08511533A (de) |
AT (2) | ATE446101T1 (de) |
AU (1) | AU693450B2 (de) |
CA (2) | CA2164291C (de) |
DE (2) | DE69435246D1 (de) |
DK (1) | DK0707487T3 (de) |
ES (2) | ES2335991T3 (de) |
MX (1) | MX263227B (de) |
PT (1) | PT707487E (de) |
WO (1) | WO1994028913A1 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5658767A (en) * | 1991-01-24 | 1997-08-19 | Martek Corporation | Arachidonic acid and methods for the production and use thereof |
US5583019A (en) | 1995-01-24 | 1996-12-10 | Omegatech Inc. | Method for production of arachidonic acid |
EP0823475B1 (de) * | 1995-04-17 | 2009-06-17 | National Institute of Advanced Industrial Science and Technology | Hoch ungesättigte fettsäurenproduzierende mikroorganismen und verfahren zur herstellung von hoch ungesättigten fettsäuren durch verwendung dieser mikroorganismen |
WO1996040106A2 (en) * | 1995-06-07 | 1996-12-19 | Martek Biosciences Corporation | Methods for controlling highly unsaturated fatty acid content in various tissues |
GB9519661D0 (en) * | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
CA2627832C (en) * | 1996-03-28 | 2012-12-11 | Dsm Ip Assets B.V. | Preparation of microbial polyunsaturated fatty acid containing oil from pasteurised biomass |
WO1997039759A2 (en) * | 1996-04-24 | 1997-10-30 | Brigham And Women's Hospital | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder |
ATE215120T1 (de) * | 1996-05-15 | 2002-04-15 | Dsm Nv | Verfahren zum extrahieren von sterol mit einem polaren lösungsmittel zur herstellung eines mikrobiellen öles mit niedrigem sterolgehalt |
GB9617847D0 (en) | 1996-08-27 | 1996-10-09 | Scotia Holdings Plc | Fatty acid treatment |
JP3792309B2 (ja) | 1996-08-30 | 2006-07-05 | サントリー株式会社 | 不飽和脂肪酸含有油脂の製造方法 |
JP4633204B2 (ja) * | 1996-10-11 | 2011-02-16 | サントリーホールディングス株式会社 | アラキドン酸含有食用油脂およびそれを含有する食品 |
US6852870B2 (en) | 1999-03-22 | 2005-02-08 | Andrew Stoll | Omega-3 fatty acids in the treatment of depression |
US6344482B1 (en) | 1997-04-23 | 2002-02-05 | Andrew L. Stoll | Omega-3 fatty acids in the treatment of bipolar disorder |
US5993221A (en) * | 1997-05-01 | 1999-11-30 | Beth Israel Deaconess Medical Center, Inc. | Dietary formulation comprising arachidonic acid and methods of use |
FR2782921B1 (fr) | 1998-09-09 | 2002-09-20 | Dior Christian Parfums | Extrait lipidique de l'algue skeletonema, procede de preparation et utilisation dans des domaines cosmetique et pharmaceutique, notamment dermatologique |
AU775421B2 (en) * | 1998-10-15 | 2004-07-29 | Dsm Ip Assets B.V. | Pufa supplements |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
US6610324B2 (en) | 1999-04-07 | 2003-08-26 | The Mclean Hospital Corporation | Flupirtine in the treatment of fibromyalgia and related conditions |
GB9923738D0 (en) * | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
EP1178103A1 (de) | 2000-08-02 | 2002-02-06 | Dsm N.V. | Reinigung von rohen PUFA-reichen Ölen |
JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
WO2004001021A1 (en) | 2002-06-19 | 2003-12-31 | Dsm Ip Assets B.V. | Pasteurisation process for microbial cells and microbial oil |
EP2295529B2 (de) | 2002-07-11 | 2022-05-18 | Basf As | Verfahren zur Verminderung von Umweltschadstoffen in einem Öl oder einem Fett und Fischfutterprodukt |
SE0202188D0 (sv) | 2002-07-11 | 2002-07-11 | Pronova Biocare As | A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
BR0314799A (pt) | 2002-09-27 | 2005-07-26 | Market Biosciences Corp | Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico |
CA2499501A1 (en) | 2002-09-27 | 2004-04-08 | Martek Biosciences Corporation | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
JP5503846B2 (ja) * | 2005-01-24 | 2014-05-28 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、dhaを含有する脂肪酸組成物の使用 |
US10086009B2 (en) * | 2005-05-23 | 2018-10-02 | Massachusetts Institute Of Technologies | Compositions containing pufa and/or uridine and methods of use thereof |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
FR2894772B1 (fr) * | 2005-12-20 | 2008-03-14 | Pierre Fabre Medicament Sa | Procede d'enrichissement en dha |
RU2437583C2 (ru) * | 2005-12-21 | 2011-12-27 | Бруди Текнолоджи, С.Л. | Применение дгк (dha), эпк (epa) или эпк, полученных из дгк, для лечения патологии, связанной с окислительным повреждением клетки, a также их нетерапевтические применения |
ES2277557B1 (es) * | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
NL1032840C2 (nl) * | 2006-11-09 | 2008-05-13 | Friesland Brands Bv | Probiotische hydrolysaatvoeding voor kinderen. |
KR101881982B1 (ko) | 2006-12-28 | 2018-07-25 | 산토리 홀딩스 가부시키가이샤 | 신경 재생제 |
DE102007031039A1 (de) * | 2007-07-04 | 2009-01-08 | Süd-Chemie AG | Verfahren zur schonenden Raffination von Pflanzenölen mit Naturbleicherde |
US20100203123A1 (en) * | 2009-02-02 | 2010-08-12 | Martek Biosciences Corporation | Methods for improving cognitive function and decreasing heart rate |
EP3926050A1 (de) | 2009-03-19 | 2021-12-22 | DSM IP Assets B.V. | Thraustochytride, fettsäurezusammensetzungen und verfahren zur herstellung und verwendungen davon |
GB0907601D0 (en) * | 2009-05-01 | 2009-06-10 | Equateq Ltd | Novel methods |
ES2758782T3 (es) * | 2010-06-01 | 2020-05-06 | Dsm Ip Assets Bv | Extracción de lípido de células y productos del mismo |
WO2012090625A1 (ja) * | 2010-12-28 | 2012-07-05 | 医療法人社団ブックス | 認知症を血液サンプルで判定するための検査方法 |
EP2709611A4 (de) | 2011-05-19 | 2014-10-29 | Univ California | Therapeutische nahrung gegen kognitiven abbau |
AU2012285803B2 (en) * | 2011-07-21 | 2016-08-25 | Dsm Ip Assets B.V. | Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof |
JP5496163B2 (ja) * | 2011-10-19 | 2014-05-21 | サントリーホールディングス株式会社 | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
FR2991337B1 (fr) * | 2012-05-29 | 2016-09-02 | Roquette Freres | Procede continu d'enrichissement en esters ethyliques de dha d'une huile produite par des microalgues |
CN115141859A (zh) | 2013-12-20 | 2022-10-04 | 玛拉可再生能源公司 | 从微生物中回收油的方法 |
WO2018091937A1 (en) | 2016-11-17 | 2018-05-24 | University Of Debrecen | Precursor compounds for providing retinoids of the vitamin a5 pathway and uses thereof |
DE102015109352A1 (de) * | 2015-06-12 | 2016-12-15 | K. D. Pharma Bexbach Gmbh | Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n) |
US10851395B2 (en) | 2016-06-10 | 2020-12-01 | MARA Renewables Corporation | Method of making lipids with improved cold flow properties |
KR101946362B1 (ko) * | 2017-10-27 | 2019-02-11 | 파이코일바이오텍코리아(주) | 뇌 염증성 질환 예방, 개선 또는 치료용 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
AU2122688A (en) * | 1987-07-20 | 1989-02-13 | Maricultura, Incorporated | Microorganism production of omega-3 (n-3) lipids |
JP2524217B2 (ja) * | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
JPH01279827A (ja) * | 1988-05-02 | 1989-11-10 | Taiyo Fishery Co Ltd | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
US5130242A (en) * | 1988-09-07 | 1992-07-14 | Phycotech, Inc. | Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids |
JP2730081B2 (ja) * | 1988-09-24 | 1998-03-25 | 日本油脂株式会社 | 微生物によるアラキドン酸含有油脂の製造方法 |
DE3920679A1 (de) * | 1989-06-23 | 1991-01-10 | Milupa Ag | Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen |
US5407957A (en) * | 1990-02-13 | 1995-04-18 | Martek Corporation | Production of docosahexaenoic acid by dinoflagellates |
PH11992043811B1 (en) * | 1991-01-24 | 2002-08-22 | Martek Corp | Arachidonic acid and methods for the production and use thereof |
EP1832181A3 (de) * | 1991-01-24 | 2010-03-31 | Martek Biosciences Corporation | Mischungen von mikrobiellen Ölen und deren Verwendungen |
GB9224809D0 (en) * | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
CA2121986A1 (en) * | 1993-04-26 | 1994-10-27 | Daizo Takeuchi | Processes for culturing marine microalgae and producing docosahexaenoic acid using the same |
-
1994
- 1994-06-02 AT AT04075413T patent/ATE446101T1/de not_active IP Right Cessation
- 1994-06-02 CA CA002164291A patent/CA2164291C/en not_active Expired - Fee Related
- 1994-06-02 JP JP7501997A patent/JPH08511533A/ja not_active Withdrawn
- 1994-06-02 DK DK94918217T patent/DK0707487T3/da active
- 1994-06-02 AT AT94918217T patent/ATE264099T1/de not_active IP Right Cessation
- 1994-06-02 DE DE69435246T patent/DE69435246D1/de not_active Expired - Lifetime
- 1994-06-02 PT PT94918217T patent/PT707487E/pt unknown
- 1994-06-02 AU AU69635/94A patent/AU693450B2/en not_active Ceased
- 1994-06-02 EP EP04075413A patent/EP1419780B1/de not_active Revoked
- 1994-06-02 CA CA2596241A patent/CA2596241C/en not_active Expired - Fee Related
- 1994-06-02 EP EP94918217A patent/EP0707487B1/de not_active Expired - Lifetime
- 1994-06-02 WO PCT/US1994/006317 patent/WO1994028913A1/en active IP Right Grant
- 1994-06-02 ES ES04075413T patent/ES2335991T3/es not_active Expired - Lifetime
- 1994-06-02 ES ES94918217T patent/ES2218525T3/es not_active Expired - Lifetime
- 1994-06-02 EP EP09013195A patent/EP2140863A1/de not_active Withdrawn
- 1994-06-02 DE DE69433713T patent/DE69433713T2/de not_active Expired - Lifetime
- 1994-06-08 MX MX9404334A patent/MX263227B/es not_active IP Right Cessation
-
2007
- 2007-12-19 JP JP2007327930A patent/JP2008133286A/ja active Pending
-
2011
- 2011-02-03 JP JP2011021979A patent/JP2011121978A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69433713T2 (de) | 2005-04-07 |
EP1419780A1 (de) | 2004-05-19 |
DE69435246D1 (de) | 2009-12-03 |
JPH08511533A (ja) | 1996-12-03 |
EP1419780B1 (de) | 2009-10-21 |
ATE264099T1 (de) | 2004-04-15 |
EP0707487B1 (de) | 2004-04-14 |
EP0707487A1 (de) | 1996-04-24 |
CA2596241A1 (en) | 1994-12-22 |
AU6963594A (en) | 1995-01-03 |
AU693450B2 (en) | 1998-07-02 |
CA2164291A1 (en) | 1994-12-22 |
DK0707487T3 (da) | 2004-08-02 |
ES2218525T3 (es) | 2004-11-16 |
CA2164291C (en) | 2007-10-30 |
JP2011121978A (ja) | 2011-06-23 |
ES2335991T3 (es) | 2010-04-07 |
EP0707487A4 (de) | 1998-09-02 |
MX263227B (en) | 2008-12-17 |
WO1994028913A1 (en) | 1994-12-22 |
CA2596241C (en) | 2011-04-19 |
ATE446101T1 (de) | 2009-11-15 |
EP2140863A1 (de) | 2010-01-06 |
PT707487E (pt) | 2004-08-31 |
JP2008133286A (ja) | 2008-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69433713D1 (de) | Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen | |
ATE210979T1 (de) | Verwendung rapamycin zur herstellung eines medikaments für die verbeugung und behandlung von hyperproliferativen gefässerkrankheiten, eventuell in kombination mit mycophenolsäure | |
DE69334294D1 (de) | Antikörper für die Behandlung von einer Immunerkrankung | |
WO1996040106A3 (en) | Methods for controlling highly unsaturated fatty acid content in various tissues | |
DE69110561D1 (de) | Mittel zur Behandlung und Vorbeugung von Bauchentzündungen, die als Wirkstoff Zink-L-Carnosin-Salze oder -Komplexe enthalten. | |
ATE238799T1 (de) | Verfahren und mittel zur arzneistoffverabreichung | |
DE69739792D1 (de) | Verfahren zur Behandlung von Augenerkrankungen | |
DE69523350D1 (de) | Behandlung von hyperproliferativen Gefässerkrankungen | |
ATE156704T1 (de) | Neurologische wirkstoffe zur nasalen verabreichung an das gehirn | |
ATE290867T1 (de) | Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten | |
ATE143261T1 (de) | Zusammensetzung zur behandlung entzündlicher darmerkrankungen | |
IL86862A (en) | Pharmaceutical compositions for reducing the level of circulating immune complexes in vivo, containing mismatched double-stranded rna | |
DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
ATE143809T1 (de) | Placentaextrakt und verfahren zu seiner herstellung | |
DE69635282D1 (de) | Behandlung der exzessiven aggressivität mit olanzapine | |
DE69218544T2 (de) | Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen | |
TR199801043T2 (xx) | Mide-ba��rsak bozukluklar�n�n �nlenmesi ve tedavisi i�in bizmut i�eren bile�imler. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |